Antinuclear antibody and anti-RNA-protein autoantibodies were determined in 143 sera containing paraproteins and 39 control sera. Antinuclear antibodies were commonly present in the paraprotein sera by indirect immunofluorescence. 19 of 143 sera (13%) had elevated anti-Ro/SSA activity in a solid phase Ro/ SSA binding assay, and 5 (3.5%) had Ro/SSA precipitating autoantibody. Eighteen sera had La/SSB binding autoantibodies (12%) but only one had an anti-La/SSB precipitin. AntinRNP(Sm) was not detected in any of these sera.
Introduction
The known specificities of myeloma proteins include a remarkable number of autoantigens, such as rheumatoid factor, blood group antigens, lipoproteins, serum albumin, peripheral nerve myelin, cytoskeletal proteins, and DNA. Antibodies to haptens and bacterial antigens have also been characterized, and several of these also bind to DNA or polyclonal IgG (1) (2) (3) . However, even after 35 yr of intense investigation into the structure and function of human myeloma proteins, the specific reactivities ofthe majority of myeloma immunoglobulins remain unknown.
Antibodies to a group of nonribosomal small RNA protein molecules are common in systemic lupus erythematosus, Sjogren's syndrome, and other rheumatic disorders and are among the autoimmune specificities that may be present in very high concentrations in some sera (4) (5) (6) (7) . These RNA protein particles are known as Ro/SSA, La/SSB, nRNP and Sm. Ro/SSA consists of a 60-kD peptide and one of four RNAs from 84 to 112 bases (8, 9) . The La/SSB protein is 43 kD and binds a number of RNAs, all of which have multiple uridine bases at the 3' end (10, 1 1). The Ro/SSA and La/SSB RNAs are generally RNA polymerase III products (12) . Sm and nRNP particles contain the U RNAs (U indicating their high uridine content). The five U6) that carry only the Sm specificity (13). The U. particle is the only one of these RNA proteins whose function is known. It contains a consensus sequence with the splice junctions of heteronuclear RNA and appears to be an important cofactor in removing introns to generate messenger RNA (14, 15) .
The appreciation that some sera containing paraproteins have had anti-Ro/SSA activity, the realization that most ofthe known specificities of myeloma proteins are autoantigens, and the finding that anti-Ro/SSA and anti-La/SSB are commonly found at low levels in normal healthy individuals (5, 16) led us to assess the frequency of these autoantibodies in sera with paraproteins and to characterize their reactivity. This analysis revealed that paraprotein sera commonly contained antinuclear antibodies. In addition, there was a high frequency of binding to Ro/SSA while anti-nRNP(Sm) activity was not found in these sera. Efforts to define the antibody population reacting with Ro/SSA showed that in each case analyzed a polyclonal anti-Ro/SSA response was present. In some Ro/SSA precipitin sera, the paraprotein also bound Ro/SSA, while in others it did not.
Methods
Sera. The sera from 143 patients with paraproteins were prospectively collected from specimens for which immunoelectrophoresis was requested at the Clinical Immunology Laboratory of the State University of New York at Buffalo. Entry to this study required only the presence of a paraprotein and, therefore, available clinical data were incomplete in many patients. From the cohort with adequate clinical data, it is estimated that 60% of these patients had multiple myeloma or Waldenstrom's macroglobulinemia while the remainder had a benign monoclonal gammopathy. Two of these patients had systemic lupus erythematosus (17) and a benign monoclonal gammopathy. Normal control sera were collected from 39 students, laboratory workers, and other colleagues. All sera were stored at -20°C for 2 yr or more.
Autoantibody assays. Precipitins against Ro/SSA, La/SSB, nRNP, and Sm were detected by Ouchterlony gel diffusion using human spleen and rabbit thymus extracts as sources of antigen. Tests for antinuclear antibodies were performed on mouse kidney frozen sections and KB tissue cell culture substrates.
The myeloma sera and 39 normal controls were screened for antiRo/SSA, anti-La/SSB, and anti-nRNP(Sm) using solid-phase enzymelinked immunosorbent assay (ELISAs)' as reported in previous studies (5, 6, 18) . Briefly, in the anti-Ro/SSA and anti-nRNP(Sm) assays, the plates were coated with affinity purified antigen from bovine spleen extract (BSE) and blocked with bovine serum albumin (BSA) before sample application. Specific activity was determined by preincubating duplicate samples with 30 Ag/ml Ro/SSA or 10 ;g/ml nRNP(Sm), respectively.
In the anti-La/SSB ELISA, the plate was coated with anti-Lal monoclonal F(ab)2 fragments, blocked, and charged with Ro/SSA depleted BSE (18) . Background was determined by comparison with duplicate wells charged with a La/SSB depleted extract. Goat anti-human IgG alkaline phosphatase conjugate (Sigma Chemical Co., St. Louis, MO) was added after sample application. The plates were developed with p-nitrophenyl phosphate and read using a MR-580 Microelisa reader (Dynatech Laboratories, Inc., Alexandria, VA). The optical density developed by a lo-' dilution ofa precipitin positive reference sera was defined as one unit of binding. In the anti-Ro/SSA assay, one unit of binding has been shown to be equivalent to the anti-Ro/SSA activity of -200 pg/mI of specifically purified anti-Ro/SSA (5). After the initial screening, anti-human IgA and anti-human IgM conjugates were used to screen patients of those paraprotein types. In addition, these conjugates were used to characterize the heavy chain type(s) of the binding antibodies; similarly, anti-human kappa and lambda light chain reagents were used to determine the light chain types. Specificity ofthese conjugates was confirmed using purified reagents collected and prepared in our laboratory.
Isoelectric properties. ofRoISSA binding immunoglobulin. An isoelectric focusing technique was developed to determine whether an individual myeloma protein bound Ro/SSA. Serum samples were run undiluted on Ampholine PAGplate pH 3.5-9.5 (LKB Instruments, Stockholm, Sweden) or 0.8% agarose/0.3% acrylamide immunoelectrophoresis gels at 4VC for 2 h at 1,500 V. Immunoglobulins were precipitated using 21% sodium sulfate. The gels were washed twice in 18% sodium sulfate and blocked for I h with 1% BSA, and the precipitated antibodies were photographed. The gels were then exposed to '25W-labeled Ro/SSA in blocking solution overnight, followed by washing for 24 h with three changes of the wash buffer. Ro/SSA antigen was radiolabeled with '25I by the lodogen method according to manufacturer's instructions (Pierce Chemical Co., Rockford, IL). The immune complexes were cross-linked with 0.1% glutaraldehyde for 1 h at room temperature, then the gels were dried. The dried gels were exposed to x-ray film for 18-24 h to detect the bands that bound the radiolabeled Ro/SSA. The autoradiographs were compared to photographs ofthe sodium sulfate precipitated immunoglobulin from the same gel to determine whether a paraprotein had anti-Ro/SSA binding.
Data analysis. In the ELISA assay, specific binding of each serum has been determined as the difference in activity before and after preincubation with antigen in the anti-Ro/SSA and anti-nRNP(Sm) assays, or the difference in wells charged with extract containing or depleted of La/SSB. The values presented are the log average of the results of two or more determinations. In the anti-Ro/SSA and anti-nRNP(Sm) assays, binding below 1 U could not be detected; since the sera were screened at a dilution of 1:250, the lowest level recorded is 250 U. The anti-La/ SSB assay is at least 10-fold more sensitive than the other ELISAs (18), so the limit of sensitivity for this assay was set at 25 U.
In the anti-Ro/SSA assay, a sample was considered positive if it had > 10,000 U of specific binding and > 50% specific inhibition. This limit was established in previous studies of normal sera when anti-Ro/SSA specific antibody was isolated from normal sera having this binding activity (5) (6) (7) (8) (18) (19) (20) 
Results
Antinuclear antibodies. The 143 sera containing paraproteins and a group of 39 normal sera were screened for antinuclear antibodies at a dilution of 1:250 on mouse kidney and KB cell substrates. None of the normals had positive fluorescence on either substrate at this dilution. On the mouse kidney substrate, 13 of the 143 paraprotein sera had antinuclear antibodies. Nuclear antigens were bound by 10 sera; 5 of these had a homogenous pattern, 2 were speckled, 1 bound the nuclear membrane, and 2 also bound the nucleolus. Seven of the positive sera were at endpoint at the 1:250 screening dilution, but in the others the antinuclear antibody test using mouse kidney tissue ranged to a high titer of 1:6750. Three sera bound cytoplasmic antigens in the mouse kidney sections. All 13 sera also bound KB cells, although many had different titers and patterns.
When KB cells were used as the antinuclear antibody substrate, over three times as many were found to be positive. Of 143 patients, 43 were positive at a dilution of 1:250, and 14 had activity at higher titers, to 1:6,750 for one patient. Most sera displayed homogenous nuclear fluorescence, but four were nucleolar, three were speckled, and eight were cytoplasmic. Two sera bound both the nucleus and the nucleolus, and one serum had both nuclear and cytoplasmic fluorescence. The highest titer serum had a cytoplasmic pattern at 1:6,750 and did not bind mouse kidney tissue sections.
Anti-RoISSA autoantibody. Anti-Ro/SSA precipitins were found in five of the 143 sera (3.5%), and these five sera also had the highest levels of binding to Ro/SSA in the solid phase assay. 14 additional sera had lower levels of positive anti-Ro/SSA binding. There was a total of 19 anti-Ro/SSA positive sera, which had a mean of 63,460 anti-Ro/SSA units of binding, and seven positive normal sera, which had a mean of 14,686 U (Fig. 1) . While the positive patients had greater Ro/SSA binding than the positive controls, most of the patients had significantly less binding than did the normal control sera (Table I) .
Anti-La/SSB and anti-nRNP(Sm) autoantibodies. An antiLa/SSB precipitin was found in one patient. This patient had the highest average level of binding in the anti-Lal ELISA and was additionally positive for both anti-Ro/SSA and antinuclear antibody. 18 patients had over 1,000 U of anti-La/SSB specific binding and were therefore considered positive in this assay (Fig.  1 ), and these patients had an average of 3,486 U of anti-La/SSB activity. There was only one positive normal, with 2,157 U of anti-La/SSB binding. Overall, normals had more anti-La/SSB than patients (217 U vs. 174 U anti-La/SSB), even though a much greater percentage of the patients were positive.
In the anti-nRNP(Sm) assay, no positives were found in either population (Fig. 1 ). This fact is significant since several positive sera were found in the other anti-RNA-protein solid phase assays. As in the other solid phase assays, the normals had significantly higher average levels of binding than did the patients (Table I) .
Relationships between autoantibodies. Many relationships have been found between the various assays used in this study (Table II) Comparisons of sera categorized by light chain type in Wilcoxon rank sum tests confirm the impression that sera with X light chain paraproteins have increased autoantibody activity; the rank difference in the groups defined by light chain type is evident in the anti-La/SSB assay and is nearly significant in the anti-Ro/SSA assays (P = 0.035 and 0.068, respectively). This difference between light chain types in the paraprotein sera is more pronounced among patients with IgG paraproteins, particularly in the anti-Ro/SSA assay (P = 0.0 13). There is no significant difference between the two light chain groups in either the antinuclear antibody assay or in the anti-nRNP(Sm) assay.
Autoimmune reactivity ofparaproteins. The next objective ofthe study was to determine the heterogeneity ofthe antibodies responsible for the autoimmune activity. The original ELISA assays, designed to detect only IgG, were modified by using conjugates directed against IgA, IgM, and the K and X light chains. The sera with IgA and IgM paraproteins were retested using the corresponding conjugates, but the only reactive sera were those that had been previously detected with the anti-IgG conjugate. Sera with previously detected IgG autoimmune activity were retested with the other four conjugates. Many sera had additional heavy chain activity, and most sera were reactive with both light chain conjugates. This data suggested that autoimmune reactivity did not necessarily correspond to and hence may not be directly related to the paraproteins or their reactivities.
The five Ro/SSA precipitin positive sera were studied in particular detail to determine whether or not the paraproteins contributed to the autoimmune activity. All five sera had high levels of IgG directed against Ro/SSA (Table IV) . In addition, patient 2, who had a X light chain Waldenstrom's macroglobulin, had both y-and At-chain activity against both Ro/SSA and La/SSB in ELISA. The isolated macroglobulin from this patient neither bound Ro/SSA in ELISA nor formed a precipitin, strongly suggesting that other immunoglobulins must be responsible for the binding activity. In patient 1, who had a XIgA paraprotein, the a-chain conjugate detected no anti-Ro/SSA activity, implying that the paraprotein did not bind Ro/SSA and, therefore, requiring that the activity observed was present in other immunoglobulins. All five sera had high levels ofbinding activity with both light chain conjugates in both the anti-Ro/SSA and antiLa/SSB assays. Therefore, while in three of five cases the paraprotein may bind Ro/SSA (or La/SSB), the response to these antigens must be polyclonal. Analysis of serum proteins by isoelectric focusing followed by binding to radiolabeled Ro/SSA provided a direct method of observing the heterogeneity of the immunoglobulin binding Ro/ SSA (Fig. 2) . Although the paraproteins of patients with cryoprecipitins were not visible in this assay, and therefore no conclusions could be reached about the paraprotein binding activity of patients 1 and 2, heterogeneous activity was clearly present in all five Ro/SSA precipitin sera (Fig. 2) reinforcing the conclusion from the solid phase assays that these responses were at least polyclonal. In addition, the binding of radiolabeled Ro/ SSA to sera from patients 4 and 5 clearly accentuated their paraprotein bands (Fig. 2, lanes 2 and 3) (Fig. 2, lane 5) . Interestingly, clinical records on these patients showed that 4 and 5 actually had systemic lupus erythematosus with a benign monoclonal gammopathy while the other three patients had multiple myeloma or Waldenstrom's macroglobulinemia without evidence of an autoimmune disease.
Discussion
In this study, we found that certain autoantibodies found in systemic lupus erythematosus are also found in patients with paraproteins. Almost one third of the sera tested had high titers of antinuclear antibodies, and more than 20% had increased levels of antibody binding to Ro/SSA and/or La/SSB, but none ofthe sera had antibodies to nRNP(Sm). Anti-Ro/SSA and antiLa/SSB antibodies were related to one another and to the presence of antinuclear antibodies. Patients with A light chain paraproteins tended to have more anti-Ro/SSA and anti-La/SSB activity than patients with K light chain paraproteins.
Solid phase assays using A and K light chain specific conjugates showed that in each positive serum, antibodies of both light chain types bound Ro/SSA or La/SSB. To confirm this finding of apparent polyclonality and to determine whether the paraprotein bound Ro/SSA in addition to the polyclonal antibodies, isoelectric focusing was performed and the antibodies binding to Ro/SSA revealed by autoradiography using '25I-labeled Ro/ SSA. This method confirmed that the paraprotein sera with antiRo/SSA activity had polyclonal anti-Ro/SSA autoantibodies. In addition, the paraprotein specificity of some of these sera (two of the three amenable to testing) was established by its binding to radiolabeled Ro/SSA. These studies confirmed earlier work suggesting that these paraproteins had anti-Ro/SSA activity. Native polyacrylamide gel electrophoresis had previously been used to isolate the paraproteins of patients 4 and 5 (Table IV) and the isolated paraproteins were shown to have Ro/SSA precipitin activity while the remaining immunoglobulin did not (Reichlin, M., unpublished data).
The frequency of paraproteins of various heavy and light chain types and electrophoretic mobilities parallels the fiequency (45, 46) . Evidence that some of these paraproteins have rheumatoid factor activity has been presented (45) but their activity against Ro/SSA and La/SSB is not known. Likewise, paraproteins are known to occur in systemic lupus erythematosus but their reactivities have not been characterized (47) .
Anti-nRNP(Sm) is also commonly present at high concentrations in systemic lupus erythematosus, but it is rarely found in other rheumatic diseases. Even low levels are rare in normal individuals (20) , and apparently anti-nRNP(Sm) is absent in patients with paraproteins. These differences between anti-Ro/ SSA and anti-nRNP(Sm) autoantibodies suggest that substantially different mechanisms are used to generate autoantibodies of the two specificities as has also been concluded from studies in normal donors (20) . It has been proposed that the risk of developing a paraprotein clone may be related to anti-idiotypic antibody and there are data supporting this possibility (48) (49) (50) (51) 
